source
- FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vaxStrain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
- Argenx reports positive Phase 3 results for Vyvgart Hytrulo in myositisArgenx announced that its subcutaneous formulation of Vyvgart, named Vyvgart Hytrulo, met the primary endpoint in a late‑stage Phase 3 trial in patients with myositis. The trial combined participa…